These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 16843263)

  • 41. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
    Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
    Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
    [TBL] [Abstract][Full Text] [Related]  

  • 42. RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapy.
    Tandon R; Senthil V; Nithya D; Pamidiboina V; Kumar A; Malik S; Chaira T; Diwan M; Gupta P; Venkataramanan R; Malik R; Das B; Dastidar SG; Cliffe I; Ray A; Bhatnagar PK
    Eur J Pharmacol; 2013 Jul; 711(1-3):19-26. PubMed ID: 23639757
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
    Kataoka Y; Mukohara T; Shimada H; Saijo N; Hirai M; Minami H
    Ann Oncol; 2010 Feb; 21(2):255-262. PubMed ID: 19633047
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.
    Kosaka T; Tanizaki J; Paranal RM; Endoh H; Lydon C; Capelletti M; Repellin CE; Choi J; Ogino A; Calles A; Ercan D; Redig AJ; Bahcall M; Oxnard GR; Eck MJ; Jänne PA
    Cancer Res; 2017 May; 77(10):2712-2721. PubMed ID: 28363995
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors.
    Kancha RK; Peschel C; Duyster J
    J Thorac Oncol; 2011 Feb; 6(2):387-92. PubMed ID: 21252719
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
    Meng X; Li Y; Tang H; Mao W; Yang H; Wang X; Ding X; Xie S
    Amino Acids; 2016 Feb; 48(2):487-97. PubMed ID: 26439378
    [TBL] [Abstract][Full Text] [Related]  

  • 47. miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2.
    Kim Y; Kim H; Park D; Han M; Lee H; Lee YS; Choe J; Kim YM; Jeoung D
    Oncotarget; 2016 Mar; 7(9):10297-321. PubMed ID: 26863629
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy.
    Zhao H; Faltermeier CM; Mendelsohn L; Porter PL; Clurman BE; Roberts JM
    Oncotarget; 2014 Dec; 5(24):12704-14. PubMed ID: 25587029
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro.
    Guo XB; Chen XJ; Tong LJ; Peng X; Huang M; Liu HC; Liu H; Ding J
    Acta Pharmacol Sin; 2015 Oct; 36(10):1266-76. PubMed ID: 26027659
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting
    Han H; Li S; Chen T; Fitzgerald M; Liu S; Peng C; Tang KH; Cao S; Chouitar J; Wu J; Peng D; Deng J; Gao Z; Baker TE; Li F; Zhang H; Pan Y; Ding H; Hu H; Pyon V; Thakurdin C; Papadopoulos E; Tang S; Gonzalvez F; Chen H; Rivera VM; Brake R; Vincent S; Wong KK
    Cancer Res; 2021 Oct; 81(20):5311-5324. PubMed ID: 34380634
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.
    Quesnelle KM; Grandis JR
    Clin Cancer Res; 2011 Sep; 17(18):5935-44. PubMed ID: 21791633
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biomarkers for predicting response to tyrosine kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells.
    Li J; Lin B; Li X; Tang X; He Z; Zhou K
    Oncol Rep; 2015 Feb; 33(2):951-7. PubMed ID: 25482142
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.
    Gaborit N; Larbouret C; Vallaghe J; Peyrusson F; Bascoul-Mollevi C; Crapez E; Azria D; Chardès T; Poul MA; Mathis G; Bazin H; Pèlegrin A
    J Biol Chem; 2011 Apr; 286(13):11337-45. PubMed ID: 21282108
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.
    Rani S; Corcoran C; Shiels L; Germano S; Breslin S; Madden S; McDermott MS; Browne BC; O'Donovan N; Crown J; Gogarty M; Byrne AT; O'Driscoll L
    Cancer Res; 2014 Jul; 74(14):3821-33. PubMed ID: 24876102
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors.
    Milik SN; Abdel-Aziz AK; Lasheen DS; Serya RAT; Minucci S; Abouzid KAM
    Eur J Med Chem; 2018 Jul; 155():316-336. PubMed ID: 29902719
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo[4,5-g]quinazolin-2(1H)-one scaffold.
    Yin S; Tang C; Wang B; Zhang Y; Zhou L; Xue L; Zhang C
    Eur J Med Chem; 2016 Sep; 120():26-36. PubMed ID: 27187856
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HER2 activating mutations are targets for colorectal cancer treatment.
    Kavuri SM; Jain N; Galimi F; Cottino F; Leto SM; Migliardi G; Searleman AC; Shen W; Monsey J; Trusolino L; Jacobs SA; Bertotti A; Bose R
    Cancer Discov; 2015 Aug; 5(8):832-41. PubMed ID: 26243863
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of Potent and Selective Covalent Inhibitors of HER2
    Hicken EJ; Brown K; Dwulet NC; Gaudino JJ; Hansen EP; Hartley DP; Kowalski JP; Laird ER; Lazzara NC; Li B; Mou TC; Mutryn MF; Oko L; Pajk S; Pipal RW; Rosen RZ; Shelp R; Singh A; Wang J; Wise CE; Wong C; Wong JY
    J Med Chem; 2024 Jun; 67(11):9759-9771. PubMed ID: 38820338
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors.
    Kuwai T; Nakamura T; Sasaki T; Kim SJ; Fan D; Villares GJ; Zigler M; Wang H; Bar-Eli M; Kerbel RS; Fidler IJ
    Neoplasia; 2008 May; 10(5):489-500. PubMed ID: 18472966
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models.
    Irie H; Ito K; Fujioka Y; Oguchi K; Fujioka A; Hashimoto A; Ohsawa H; Tanaka K; Funabashi K; Araki H; Kawai Y; Shimamura T; Wadhwa R; Ohkubo S; Matsuo K
    Mol Cancer Ther; 2019 Apr; 18(4):733-742. PubMed ID: 30787176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.